Tagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

UK pharma major AstraZeneca today revealed that, this week, it has received two positive recommendations from the National ...

Analyst Andrew Berens of Leerink Partners maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of ...

AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general ...

The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.

AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), ...

AstraZeneca share rose after it that the company has secured permission to import pharmaceutical formulations of new drug for ...

The Pharmaceutical Technology Excellence Awards winners have been announced! Download our full 50+ page report to find out ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...